Is Virax Biolabs Group Ltd (VRAX) Stock a Good Investment?
Learn more about Virax Biolabs Group Ltd's (VRAX) stock grades for Growth and determine whether this Biotechnology & Medical Research stock meets your investment needs.Jack Gilleland
Stock Evaluator: Virax Biolabs Group Limited (VRAX)
Virax Biolabs Group Limited VRAX
$3.19
-0.26
-7.54%
August 21, 2026 4:00:00 PM
EST
Volume: 118,985
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Health Care Providers & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China. The company offers ViraxImmune, a T cell-based immune profiling and diagnostic platform for post-acute infection syndromes, including long COVID, myalgic encephalomyelitis / chronic fatigue syndrome, and post-treatment Lyme disease. It also provides ImmuneSelect, a research-use-only portfolio of peptide pool ELISpot plates and related immune reagents. In addition, the company is involved in research and development activities and the provision of procurement, warehousing, product development, and staffing management services. It serves research organizations, academic institutions, contract research organizations, biopharmaceutical companies, independent laboratories, and distributors. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, United Kingdom.
Commentary & Analysis
Financial Summary
| Share Statistics | VRAX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2.5 | $1,968.0 | 1% |
|
| Shares Out (Mil) | 0.6 | 77.7 | 3% |
|
| Institutional Ownership | 47.6% | 86.6% | 21% |
|
| Float (Mil) | 0.7 | 52.1 | 2% |
|
| Beta | 1.33 | 0.75 | 78% |
|
| Avg Daily Volume (000s) | 1,897 | 612 | 81% |
|
| Price Change (52-week) |
(83.3%) | 79.8% | 6% |
|
| Growth | VRAX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 10.9% | na |
|
| Net Income (5yr) | (48.2%) | (1.6%) | 7% |
|
| EPS (5yr) | na | 0.3% | na |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (17.9%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | VRAX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $1,504 | na |
|
| Net Income (TTM) (Mil) | ($5) | $28 | 33% |
|
| EPS (TTM) | ($12.636) | $0.200 | 3% |
|
| Operating Cash Flow (TTM) (Mil) | ($5) | $162 | 25% |
|
| Net Cash Flow (TTM) (Mil) | $2 | $9 | 48% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $338 | 13% |
|
| Enterprise Value (Q1) (Mil) | ($4) | $2,416 | 2% |
|
| Valuation | VRAX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.24 | 2.82 | 3% |
|
| P/E | na | 26.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | VRAX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 61.9% | 27.8% | 74% |
|
| Net Margin | na | 1.2% | na |
|
| ROA | (68.1%) | 2.2% | 9% |
|
| ROE | (75.7%) | 7.2% | 12% |
|
| Liabilities to Assets | 11.9% | 58.6% | 7% |
|
| F-Score | 6 | 5 | 67% |
|
Virax Biolabs Group Limited did not pass any screens on 8/21/2026.
